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once-a-day. Such lower peak plasma concentrations might not
reach the pharmacologically effective threshold and could ex-
plain the lack of efﬁcacy of glucosamine hydrochloride observed
in GAIT compared to the GUIDE and previous long-term trials of
crystalline glucosamine sulfate. Combination of glucosamine hy-
drochloride with chondroitin sulfate further reduces glucosamine
bioavailability.
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Purpose: While systemic administration of interleukin-1 (IL-1)
receptor antagonist (IL1Ra) is approved for treating RA, a high
incidence of side effects and need for frequent dosing does
not suggest utility for treating OA. Local delivery of an IL1Ra-
containing drug depot could provide for sustained drug presence,
decreased dosing requirements, and reduce systemic toxicity for
OA. Elastin-like polypeptides (ELPs) have been developed as
injectable, and thermally-responsive intra-articular drug depots.
ELPs had a joint space half-life 25-fold greater than that of
comparable non-responsive proteins. Here we evaluate the ac-
tivity of an intra-articular injection of IL1Ra conjugated to ELP in
attenuating IL-1β induced pathology in a rat knee joint model.
Methods:A fusion protein of human IL1Ra and ELP (ELP-IL1Ra)
was synthesized as described previously. Right knee joints of 18
rats were injected with 12,500 rat dermal ﬁbroblasts modiﬁed to
over-express human IL-1β. After 24h, 6 rats each received one of
the following injections: ELP-IL1Ra fusion protein (120µg), com-
mercial IL1Ra (0.24µg), or no treatment. Protein doses insured
that IC50 values were equal for fusion and commercial IL1Ra.
Daily weights, coronal and sagittal knee joint diameters were
recorded. After 7 days, rats were sacriﬁced and right knees eval-
uated for grade of gross pathology (0-2, 0 = non-degenerate).
Joints were placed in explant culture for 24h and human and
rat IL-1β expression was measured in supernatants via ELISA.
Joint sections were evaluated for histological evidence of OA
(OARSI Histopathology Assessment; 0-6, 0 = non-degenerate).
All data are reported relative to contralateral controls. Chi-square
analysis was performed on gross and OARSI grades; one-way
ANOVA was performed on body weights, knee joint diameters,
and ELISA data. Bonferroni post-hoc analyses were used.
Results: There was no difference in body weight gain, or coronal
or sagittal knee joint diameters amongst groups. Gross pathology
was different amongst groups (p<0.04, Chi-square, Table). The
ELP-IL1Ra group had less pathology than no treatment animals
(p<0.01, Figure 1). OARSI grades were signiﬁcantly lower for
Figure 1. Images of ﬁbroblast injected knee joints receiving no treatment (a),
commercial IL-1Ra (b), or the ELP-IL1Ra fusion protein (c).
Table 1. Grades relative to contralateral control
Gross grades OARSI grades
Femoral Femoral Tibial
groove condyle plateau
ELP-IL1Ra 0.17±0.93* 2.8±2.2* -0.17±1.6* -0.83±1.8
Commercial rhIL1Ra 1.1±0.74 4.6±2.6 2.2±2.4 4.0±2.0
No treatment 1.7±0.3 4.3±3.1 5.5±0.84 1.5±2.5
*Signiﬁcant difference from no treatment group, Bonferroni post-hoc test.
the ELP-IL1Ra group at patellofemoral (p<0.006) and condylar
sites (p<0.015), but not tibial plateau, compared to no treatment
animals (Table 1). There was no statistical difference between
commercial IL1Ra and either no treatment or ELP-IL1Ra groups
in gross pathology or OARSI grades. There was no difference
in amount of human or rat IL-1β in explant cultures indicating
that all groups had the same potential to develop pathological
changes.
Conclusions: These data show efﬁcacy for the ELP-IL1Ra fu-
sion protein in mediating effects of IL-1β induced knee pathology.
Single intra-articular administration of the fusion protein ELP-
IL1Ra has the potential for release of an active IL1Ra domain
for up to 4 weeks in the rat model, and may have potential to
provide therapeutic effects when delivered locally in patients with
OA.
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Purpose: In osteoarthritis (OA) pain, and not the structural
changes in the joint, are the main reason for a patient to seek
medical attention. The exact origin of joint pain in OA is hardly
known, but undoubtedly pain is related to the secondary inﬂam-
matory responses in OA. This inﬂammation contributes to joint
damage and therefore, by diminishing inﬂammation pain will be
diminished and development of OA will be slowed down. NSAIDs
and COXIBs might be useful in this respect, although with re-
strictions. Therefore, the need remains for alternatives, of which
many presently under investigation. Glycine might be a novel
candidate in this respect. Glycine as a single molecule has anti-
inﬂammatory capacities; amongst others, dietary glycine showed
an inhibitory effect on the development of arthritis (Li X, e al.
Infect Immun 2001; 69: 5883-). In the present study glycine was
evaluated as a dietary supplement on the development of OA.
For this purpose we choose an experimental canine OA model
with moderate but clearly evident synovial inﬂammatory activity;
the ACLT model combined with medial meniscectomy (Mx).
Methods:Knee osteoarthritis (OA) was induced in dogs by ACLT-
Mx (n=12). Double blind, either glycine (10g/dog) or placebo was
given orally daily, every morning at the same time before the
meal was given. Longitudinal as well as endpoint parameters of
cartilage damage, synovial inﬂammation and pain were evalu-
ated.
Results: Twelve weeks post-surgery OA characteristics were
clearly present; radiographs revealed progressive osteophyte
formation in the experimental joints (p<0.05). Gait analysis re-
